ORAMED PHARMACEUTICALS INC.
ORAMED PHARMACEUTICALS INC. (ORMP): 3 pipeline candidates · 1 upcoming catalyst · ~34 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
33.9 months
3% dilution
Lead: Phase 3
3 candidates
1 upcoming, next in ~338d
N/A
A transparent, data-derived signal for ORAMED PHARMACEUTICALS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$155.1M
Cash
$13.2M
Quarterly Burn
$2.9M
Runway
33.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| oral insulin | Preclinical |
| oravax oral vaccine | Phase 1 |
| ormd-0801 | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
60
Total value held
$23.2M
| Holder | Shares | Value |
|---|---|---|
| aquamarine financial (cayman) ltd | 2,112,312 | $7.2M |
| mercer global advisors inc /adv | 1,910,540 | $6.5M |
| boothbay fund management, llc | 600,716 | $2.0M |
| marshall wace, llp | 259,611 | $883K |
| dimensional fund advisors lp | 158,209 | $538K |
| wells fargo & company/mn | 157,586 | $536K |
| ritholtz wealth management | 155,479 | $529K |
| renaissance technologies llc | 147,700 | $502K |
| bank of america corp /de/ | 146,152 | $497K |
| susquehanna international group, llp | 136,218 | $463K |
Showing top 10 of 60 institutional holders of ORAMED PHARMACEUTICALS INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ORAMED PHARMACEUTICALS INC.'s pipeline?
ORAMED PHARMACEUTICALS INC. (ORMP) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ORAMED PHARMACEUTICALS INC.'s lead drug candidate?
ORAMED PHARMACEUTICALS INC.'s most advanced tracked candidate is oral insulin (Preclinical) for diabetes.
What is ORAMED PHARMACEUTICALS INC.'s next catalyst?
ORAMED PHARMACEUTICALS INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evalua" — expected May 22, 2027.
What is ORAMED PHARMACEUTICALS INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ORAMED PHARMACEUTICALS INC. has approximately 33.9 months of cash runway.
What is ORAMED PHARMACEUTICALS INC.'s market capitalization?
ORAMED PHARMACEUTICALS INC.'s market capitalization is approximately $155.1M.
Get the full picture on ORAMED PHARMACEUTICALS INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.